US Patent

US10092541 — Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast

Method of Use · Assigned to Celgene Corp · Expires 2034-05-29 · 8y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods for treating diseases such as psoriasis and rheumatoid arthritis using apremilast in a specific dosage titration schedule.

USPTO Abstract

Methods of treating, managing or preventing diseases ameliorated by inhibiting PDE4 such as psoriasis, ankylosing spondylitis, Behcet's disease, rheumatoid arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis are disclosed. Specific methods encompass the administration of apremilast in specific dosage titration schedule, alone or in combination with a second active agent.

Drugs covered by this patent

Otezla (APREMILAST) · Amgen

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2659`	—	Otezla
`U-2403`	—	Otezla
`U-2403`	—	Otezla
`U-2659`	—	Otezla

Patent Metadata

Patent number: US10092541
Jurisdiction: US
Classification: Method of Use
Expires: 2034-05-29
Drug substance claim: No
Drug product claim: No
Assignee: Celgene Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.